MedTrace Logo

Mitomycin-C Injection Therapy in Refractory Esophageal Stricture

NCT04284826 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-02-28

No results posted yet for this study

Summary

Intralesional Mitomycin-C (MMC) injection has recently been introduced to resolve refractory benign esophageal stricture mostly in children. The investigators aimed to evaluate the clinical efficacy of endoscopic postdilation intralesional injection of MMC in adults with refractory benign esophageal stricture.

Conditions

  • Esophageal Stricture

Interventions

PROCEDURE

Endoscopic injection of Mitomycin-C on bougie-dilated refractory benign esophageal stricture

Sponsors & Collaborators

  • Ajou University School of Medicine

    lead OTHER

Principal Investigators

  • Jin Hong Kim · Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
29 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-01
Primary Completion
2018-08-31
Completion
2018-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04284826 on ClinicalTrials.gov